Trendlines Group - TRNLY STOCK NEWS

ZygoFix, a Trendlines portfolio company, has received FDA clearance for its zLOCK Lumbar Facet Fixation System, revolutionizing spinal fusion surgery. The system, backed by strong clinical evidence, offers a minimally invasive procedure with long-term pain reduction benefits. With CE certification and successful clinical utilization, ZygoFix is poised to make a significant impact in the US market.

Arcuro Medical appointed Jamal Rushdy, a seasoned MedTech industry veteran, as its new CEO. Rushdy brings over 28 years of experience in orthopedics and sports medicine. The company aims to enhance patient care with their SuperBall™ technology for meniscus repair. Lee Ranon, the co-founder, transitions to the COO role. The board expresses confidence in Rushdy's leadership for the company's growth.

Vessi Medical Ltd. closes a $16.5 million Series A financing round for its cryotherapy technology to treat Non Muscle Invasive Bladder Cancer, with key investors including an undisclosed global strategic investor, ALIVE- Israel HealthTech Fund, and Agriline. The technology aims to provide a minimally invasive solution for NMIBC, potentially improving quality of life. The financing will support R&D, clinical studies, and regulatory clearance to bring the treatment to patients.

liberDi Ltd., a portfolio company of The Trendlines Group, has received FDA clearance for its Digital Dialysis Clinic, allowing patients to perform home dialysis independently with physician monitoring. This advancement aims to improve the quality of life for dialysis patients, who often spend significant time in clinics. The system has demonstrated safety and effectiveness in clinical studies involving 42 subjects and is positioned to disrupt traditional dialysis methods. The technology leverages telemedicine for enhanced patient care.

The Trendlines Group Ltd. (OTCQX: TRNLY) has established a new company, Celleste Bio, aimed at producing high-value cocoa ingredients through cell culture methods. This innovation reduces dependency on cocoa tree cultivation and addresses sustainability challenges associated with traditional cocoa farming. Co-investors include Mondelēz International and Barrel Ventures. Celleste's technology ensures consistent cocoa yields, unaffected by climate. By utilizing naturally occurring cocoa cells, the company aligns with growing consumer demand for environmentally friendly products.

The Bayer Trendlines Ag Innovation Fund has established TierraSpec, a company focused on remote measurement and validation of carbon sequestration in agricultural soil. Utilizing over 30 years of research from Tel Aviv University, TierraSpec aims to provide cost-effective technology for carbon credit issuance and soil health monitoring. This innovation addresses the limited eligibility of agricultural projects for carbon credits, currently at only 1-2%. With a US$10 million investment from Bayer, the initiative supports sustainable agricultural practices and effective carbon reporting.

Escala Medical received FDA clearance for its first pelvic organ prolapse repair device following the successful completion of a one-year follow-up on a first-in-human clinical study involving 17 patients. This device offers a safe, incision-free repair option for women with pelvic organ prolapse, a condition affecting nearly 50% of women globally. Escala's procedure takes less than 10 minutes, enhancing the quality of life for women. Notably, Dr. Mickey Karram joined the Scientific Advisory Board, further strengthening Escala's market position.

Arcuro Medical Ltd. has appointed Dr. Phil Davidson as Medical Director and Dr. Ken Zaslav to its Scientific Advisory Board (SAB). The SAB aims to advance Arcuro's clinical development pipeline, particularly focusing on the SuperBall® Meniscal Repair System, which has successfully treated over 500 patients since receiving FDA approval in June 2018. CEO Lee Ranon emphasized the expertise of the SAB members in enhancing product development and market leadership in meniscal repair devices.

SetBone Medical Ltd., based in Israel, has successfully closed an oversubscribed investment round raising $1.6 million. This funding, backed by notable investors like The Trendlines Group (SGX: 42T) and Agriline, will facilitate the next phase of development and the initiation of a First in Human pilot study. SetBone's innovative bone cement addresses limitations in current orthopedic solutions and aims to capture a share of the projected $1.4 billion bone cement market by 2028, targeting conditions like Vertebral Compression Fractures.